ZeVra Therapeutics saw its shares rise 29% over two days after its drug Miplyffa for Niemann-Pick Disease Type C was granted patent exclusivity through 2041 via the FDA Orange Book listing. The company reported $87.4 million in net sales for FY25, achieved profitability, retired all debt, and holds $236.8 million in cash and investments. Its pipeline focuses on celiprolol for VEDS with orphan and breakthrough therapy designations, facing no clinical competition. Trading at about 9 times estimated FY27 earnings per share, ZeVra offers growth potential, a strong balance sheet, and possible acquisition appeal, making it a candidate for a small investment position.
Technical analyst Katie Stockton of Fairlead Strategies indicates that Bitcoin may have reached a major low after nearing $60,000, based on rare long-term oversold signals from key indicators. This suggests the recent price decline might be ending, w...
SpaceX reported a 92% year-over-year revenue increase in Q2 to $7.81 billion, but its capital expenditures surged to $18.37 billion, largely driven by $15.83 billion spent on AI infrastructure. The company faces challenges as Starlink's average reven...
The optical industry's two largest laser chip suppliers, Lumentum Holdings and Coherent Corp., confirmed a severe supply shortage driven by rising demand for AI-related optical solutions. This shortage is causing major customers to seek alternative s...
Multicoin Capital has invested over $100 million in Hyperliquid's native token, HYPE, highlighting strong institutional confidence in the Layer 1 blockchain's business model. Hyperliquid operates a decentralized perpetual futures exchange and aims to...
Chinese robot maker Unitree is going public with an IPO valuation of about $9 billion at 150.80 yuan ($22.37) per share on the Shanghai STAR Market. However, pre-IPO perpetual futures traded on Hyperliquid value the company at nearly $38 billion, ove...
